Quality investing is built on a simple premise: own companies that can grow profitably and generate cash for many years rather than focus on short-term price swings. The Caviar Cruise screen translates that idea into concrete, measurable filters, combining revenue and profit growth requirements with high returns on invested capital, manageable debt, and a track record of converting earnings into free cash flow. AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) stands out within this framework, and the numbers behind its screening profile show why it earns a spot on the radar of quality-oriented investors.
What the Caviar Cruise screen looks for
The screen, inspired by Luc Kroeze's work on quality investing, starts with a set of non-negotiable criteria. It seeks companies that have grown revenue and operating profit at a healthy clip over the past five years, with EBIT growth outpacing revenue growth as evidence of improving profitability. It also demands a return on invested capital above 15%, a debt load that can be paid off within five years using free cash flow, and profit quality above 75%.
Where Amphastar fits
Measured against those criteria, Amphastar posts several strong results:
- EBIT growth over five years of 66.4%, well above the 5% minimum and far ahead of revenue growth, pointing to strong operating leverage
- ROIC excluding cash, goodwill, and intangibles of 17.2%, above the 15% quality threshold
- Debt to free cash flow of 4.0, meaning the company could repay its debt in about four years of current free cash flow
- Average profit quality of 104% over the past five years, indicating that net income is fully backed by free cash generation
The notable exception is revenue growth. The five-year CAGR of roughly 3.0% falls below the screen's 5% threshold. That is a real caveat for quality investors, but it is worth weighing against the exceptionally strong EBIT growth and high cash conversion, which suggest the business is creating value from existing operations even when the top line grows slowly.
Why these criteria matter
Quality investing is not just about picking companies with strong historical numbers. It is about identifying businesses that can sustain their performance over a full market cycle. A high ROIC signals that management reinvests capital efficiently. EBIT growth above revenue growth points to pricing power or economies of scale. A moderate debt-to-FCF ratio keeps the balance sheet resilient during downturns, and high profit quality ensures that reported earnings are backed by cash rather than accounting adjustments.
Amphastar fits that profile on several fronts. The company develops and markets technically challenging injectable, inhalation, and intranasal products, along with insulin active pharmaceutical ingredients, and most of its finished products are used in hospital or urgent care settings. That positioning gives it a defensible niche that helps explain the strong profitability and cash conversion captured by the screen.
What the fundamental report shows
The broader fundamental assessment reinforces several of the screen's findings. Amphastar scores 6 out of 10 overall, with the strongest contributions coming from profitability and valuation.
- Profitability scores 9 out of 10, with an operating margin of 15.7% and a profit margin of 10.8%, both ranking among the better half of the pharmaceuticals industry
- Valuation scores 8 out of 10, with a trailing P/E of roughly 7.0 and a forward P/E of 6.8, far cheaper than both the industry average and the S&P 500
- Financial health scores 6 out of 10; the current ratio of 2.4 points to solid short-term liquidity, but the Altman-Z score of 2.0 sits in the grey zone and the debt-to-equity ratio of 0.79 is higher than many peers
- Growth scores 4 out of 10; the five-year EPS growth of 38.4% is strong, but a recent trailing EPS decline of 13.8% and expectations for softer future growth temper the picture
Investors who want to review the full breakdown can open the fundamental analysis report.
Risks and limitations
No screen is a complete substitute for research, and Amphastar has weaknesses that deserve attention. The most obvious is revenue growth below the screen's threshold. While EBIT growth has been exceptional, the modest top-line expansion means the company may not compound as quickly as other quality candidates. In addition, consensus estimates point to a slight decline in earnings per share over the coming years, and the recent drop in EPS growth is a reminder that past performance does not guarantee future results. The Altman-Z score also suggests the balance sheet carries some risk, even though the debt-to-FCF position looks manageable.
Another screen flags the same cash strength
Amphastar’s cash generation is strong enough that it also shows up in Chartmill’s High Free Cash Flow Stocks screen. That screen combines strong free cash flow with quality and liquidity filters, so its inclusion reinforces the article’s point that AMPH’s earnings are backed by real cash rather than just accounting adjustments.
The bottom line
For quality investors, Amphastar offers several of the essential ingredients: strong profitability, high returns on invested capital, excellent cash conversion, and an appealing valuation. The softer revenue growth and mixed earnings outlook are reasons to investigate further rather than to dismiss the stock outright. Within the quality investing framework, the stock illustrates that a disciplined screen can uncover interesting candidates, but the final decision always requires judgment beyond the numbers.
Investors who want to apply the same methodology more broadly can use the stock screener to identify additional companies that meet these quality criteria.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.
Read full article here »
View the Zacks #1 Rank List
Amphastar Pharmaceuticals (NASDAQ:AMPH) Stands Out as a Quality Investing Candidate
Quality investing is built on a simple premise: own companies that can grow profitably and generate cash for many years rather than focus on short-term price swings. The Caviar Cruise screen translates that idea into concrete, measurable filters, combining revenue and profit growth requirements with high returns on invested capital, manageable debt, and a track record of converting earnings into free cash flow. AMPHASTAR PHARMACEUTICALS IN (NASDAQ:AMPH) stands out within this framework, and the numbers behind its screening profile show why it earns a spot on the radar of quality-oriented investors.
What the Caviar Cruise screen looks for
The screen, inspired by Luc Kroeze's work on quality investing, starts with a set of non-negotiable criteria. It seeks companies that have grown revenue and operating profit at a healthy clip over the past five years, with EBIT growth outpacing revenue growth as evidence of improving profitability. It also demands a return on invested capital above 15%, a debt load that can be paid off within five years using free cash flow, and profit quality above 75%.
Where Amphastar fits
Measured against those criteria, Amphastar posts several strong results:
The notable exception is revenue growth. The five-year CAGR of roughly 3.0% falls below the screen's 5% threshold. That is a real caveat for quality investors, but it is worth weighing against the exceptionally strong EBIT growth and high cash conversion, which suggest the business is creating value from existing operations even when the top line grows slowly.
Why these criteria matter
Quality investing is not just about picking companies with strong historical numbers. It is about identifying businesses that can sustain their performance over a full market cycle. A high ROIC signals that management reinvests capital efficiently. EBIT growth above revenue growth points to pricing power or economies of scale. A moderate debt-to-FCF ratio keeps the balance sheet resilient during downturns, and high profit quality ensures that reported earnings are backed by cash rather than accounting adjustments.
Amphastar fits that profile on several fronts. The company develops and markets technically challenging injectable, inhalation, and intranasal products, along with insulin active pharmaceutical ingredients, and most of its finished products are used in hospital or urgent care settings. That positioning gives it a defensible niche that helps explain the strong profitability and cash conversion captured by the screen.
What the fundamental report shows
The broader fundamental assessment reinforces several of the screen's findings. Amphastar scores 6 out of 10 overall, with the strongest contributions coming from profitability and valuation.
Investors who want to review the full breakdown can open the fundamental analysis report.
Risks and limitations
No screen is a complete substitute for research, and Amphastar has weaknesses that deserve attention. The most obvious is revenue growth below the screen's threshold. While EBIT growth has been exceptional, the modest top-line expansion means the company may not compound as quickly as other quality candidates. In addition, consensus estimates point to a slight decline in earnings per share over the coming years, and the recent drop in EPS growth is a reminder that past performance does not guarantee future results. The Altman-Z score also suggests the balance sheet carries some risk, even though the debt-to-FCF position looks manageable.
Another screen flags the same cash strength
Amphastar’s cash generation is strong enough that it also shows up in Chartmill’s High Free Cash Flow Stocks screen. That screen combines strong free cash flow with quality and liquidity filters, so its inclusion reinforces the article’s point that AMPH’s earnings are backed by real cash rather than just accounting adjustments.
The bottom line
For quality investors, Amphastar offers several of the essential ingredients: strong profitability, high returns on invested capital, excellent cash conversion, and an appealing valuation. The softer revenue growth and mixed earnings outlook are reasons to investigate further rather than to dismiss the stock outright. Within the quality investing framework, the stock illustrates that a disciplined screen can uncover interesting candidates, but the final decision always requires judgment beyond the numbers.
Investors who want to apply the same methodology more broadly can use the stock screener to identify additional companies that meet these quality criteria.
Disclaimer: This article is for informational and educational purposes only and does not constitute financial advice or a recommendation to buy or sell any security. Always conduct your own research and consider your risk tolerance before making investment decisions.
Read full article here »